Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Afatinib · 1 trial · 3 indications
Percentage of patients, interested in participating, consented and detected with target mutations and completed the treatment with one of the 5 study drugs
| Arm | Type | Description |
|---|---|---|
| Treatment | EXPERIMENTAL | Patients will receive one of the 5 study drugs based on their recurrent tumor mutation profile and their recurrent organoid response to these drugs: 1. Afatinib 2. Dasatinib 3. Palbociclib 4. Everolimus 5. Olaparib |
| Name | Type | Description |
|---|---|---|
| Afatinib | DRUG | Afatinib will be administered orally at a dose of 40 mg daily in patients with EGFR amplification. |
| Dasatinib | DRUG | Dasatinib will be administered orally at a dose of 100 mg once daily in patients with PDGFR amplification. |
| Palbociclib | DRUG | Palbociclib will be administered orally at a dose of 125 mg once daily in patients with CDK4 and CDK6 amplification. |
| Everolimus | DRUG | Everolimus will be administered orally at a dose of 10 mg daily in patients with PI3K/PTEN/mTOR activated pathways. |
| Olaparib | DRUG | Olaparib will be administered orally at a dose of 300 mg twice daily in patients with TP53 mutation. |
Inclusion Criteria: 1. Study participant has provided informed consent prior to initiation of any study specific activities/procedures. 2. Adult participants, male and female, aged ≥18 who have a pathologically confirmed IDH-wild type glioblastoma, with first or second progression of the tumor, aft...
Afatinib is being studied as a treatment for recurrent glioblastoma, a type of brain cancer. It is currently in early Phase 1 clinical development for this indication. The drug is being evaluated in a pilot trial enrolling patients with recurrent glioblastoma who are at least 18 years old.
Afatinib is a small molecule kinase inhibitor, belonging to the -tinib class of drugs. It works by inhibiting certain kinase enzymes, which are involved in cell signaling and growth. This mechanism is being explored in the context of treating recurrent glioblastoma, where kinase activity can drive tumor progression.
Afatinib is being developed by Avalon GloboCare Corp., a biopharmaceutical company traded under the ticker ALBT. The company is conducting a Phase 1 clinical trial for the drug in recurrent glioblastoma. This trial is currently recruiting participants in Canada.
Afatinib is in early Phase 1 clinical development for recurrent glioblastoma. The ongoing trial is an early Phase 1 study, meaning it is in the initial stage of testing in humans. The drug is investigational and has not yet been approved for this use.
Afatinib is being studied in a single clinical trial identified as NCT05432518, titled "Pilot Trial for Treatment of Recurrent Glioblastoma." This is an early Phase 1, uncontrolled, open-label study with a planned enrollment of 10 participants. The trial is currently recruiting and is being conducted in Canada.
Afatinib is a distinct drug entity and is not known by alternative names in the context of this development program. It is a small molecule kinase inhibitor being investigated for recurrent glioblastoma by Avalon GloboCare Corp. No other names for this drug have been associated with this specific trial.